Luitpold Recalls Additional Hydralazine Injection Lots
This article was originally published in The Pink Sheet Daily
Daiichi Sankyo subsidiary says it is investigating problem of possible particulate contamination.
You may also be interested in...
Phase I compound AJD101 has a new mechanism of action that stimulates insulin independent glucose uptake in preclinical studies, according to the two Tokyo-based drug makers.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.